| Previous Close | 6.07 |
| Open | 6.19 |
| Bid | 6.25 x N/A |
| Ask | 6.28 x N/A |
| Day's Range | 6.11 - 6.28 |
| 52 Week Range | 4.32 - 12.62 |
| Volume | 13,912 |
| Avg. Volume | 65,458 |
| Market Cap | 558.199M |
| Beta (5Y Monthly) | 1.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.85 |
| Earnings Date | May 03, 2021 - May 07, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference: Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference Panel: Opportunities in BPDCN and AML Date:Thursday, April 15, 2021 Time:3:00 – 3:55 PM EDT Format:Panel Moderated by John Newman, Ph.D., Managing Director, Biotechnology Analyst Conference Information: Link The Aptose management team also will be hosting 1x1 meetings during the event. About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: luxeptinib (CG-806), an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical-stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS). For further information, please contact: Aptose Biosciences Inc. Susan Pietropaolo Investor Relations 201-923-2049spietropaolo@aptose.com LifeSci Advisors, LLC Dan Ferry, Managing Director 617-535-7746 Daniel@LifeSciAdvisors.com
- The Motley Fool
5 Top TSX Stocks to Buy Amid a Market Rally in April 2021
Investors can buy these five rallying stocks in April 2021 to benefit from the ongoing market rally. The post 5 Top TSX Stocks to Buy Amid a Market Rally in April 2021 appeared first on The Motley Fool Canada.
- Motley Fool
Why Aptose Biosciences Stock Is Skyrocketing Today
The huge gain came after the company provided a fourth-quarter update following the market close on Tuesday that featured new results from an early-stage clinical study evaluating luxeptinib in treating acute myeloid leukemia (AML). Aptose announced "encouraging anti-leukemic activity" has been observed so far in its phase 1 study of luxeptinib in treating AML. One patient in the study has experienced a complete remission with no safety issues.
